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Physicians in an attempt to give their patients the best possible care need to be updated on
the evolving body of scientific research, trials, case reports, and combine this evidence with
their own clinical experience keeping in mind each individual patient's circumstances and
preferences. To address this felt need, guidelines are systematically developed statements
designed to help clinicians make management decisions. While a multitude of guidelines
are available from developed world they might not exactly fit into developing world
context. Thus a host of fresh guidelines might be required to fill this void or the existing
guidelines modified (supplemented, altered or deleted) to be relevant to this part of the
world.
Copyright © 2015, Cardiological Society of India. All rights reserved.1. Introduction
During the course of their daily practice, physicians are con-
fronted by clinical situations which are of considerable sig-
nificance but have no unequivocal guidance for their
management. The issue could pertain to avoidable morbidity
andmortality, inappropriate variation in performance, and/or
un-necessary expenditure on a health service.1 While data
may be available to address these issues, a busy practitioner
may find it difficult to sift through it, analyze it and reach to an
unambiguous decision. Clearly, the clinical topic warrants
prioritization and even development of a guideline to address
the problem. While previously existing guidelines (from
developed nations) are often freely available, each society has
its own national and/or regional challenges and priorities.
While there is no sense in “inventing the wheel again”, manyl.com (S. Mishra).
ociety of India. All rightsWestern developed guidelines may not exactly fit into a
regional context. On the other hand, development of brand
new clinical guidelines requires extensive material as well as
man-power resources. Generally the stumbling block is lack of
locally relevant evidence base and the absence of appropri-
ately skilled and experienced individuals with enough time to
spare for this activity.2 Often the best bet is identifying a
previously developed rigorous guideline and contextualizing
and adapting it for local use, thus developing a cost-efficient
approach to promote evidence-based practice.2. Why do we need Indian guidelines?
The world is not homogenous nor is the human being! There
are variations in the genetic make-up, health-care practices
and availability of resources and funds across differentreserved.
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oped’ World. Thus there are areas in cardiovascular disease
where an Indian population has a different need and therefore
require a different solution. The second question is who are
the people who should be writing these guidelines? The
fundamental purpose of a guideline committee should be to
add value and stature to the guideline, and not the other way
around. That may be a reason why so many Indian guidelines
appeared and then were confined to the “flames of history.”
Thus the need of the hour is not to prepare a “me too”
guideline which is essentially a rehash of the western guide-
lines but to carefully identify those areas where the need of
new guidelines exist, owing to genetic, demographic, clinical
and socio-economic differences of the South Asian population
from those in developed nations. An equally important and
simultaneous effort should be critical appraisal of local data
and initiation of the process to generate this data in areas of
perceived need. Finally, once the guidelines are developed
they should be effectively communicated not only to the
medical and para-medical personnel but also among other
stake holders like hospital administrators, insurers, and gov-
ernment and regulatory bodies.3. Factors to be considered while making
guidelines
3.1. Genetic-make up
Genotypic and phenotypic diversity have been found in all
species at all organizational levels. This diversity is
nonrandom, heavily structured, and correlated with envi-
ronmental variation and stress.3 Genetic diversity serves as a
way for populations to adapt to changing environments.
However, this very diversity is responsible for variations in
disease susceptibility, response to environmental triggers,
response to drugs and other therapeutic interventions. Thus it
is important to understand how this genetic variability im-
pacts on the interpretation of human data developed from
other population groups. An excellent example is insulin
resistance (thrifty gene) phenotype of South Asians which
impacts the lipid profile of the individuals of this region, being
characterized by not only high LDL cholesterol but also low
HDL cholesterol and high triglyceride level (very different
fromwestern populations who have only high LDL).4 Thus the
lipid treatment thresholds and effect sizes may be different
and relations of various lipid sub-fractions with vascular dis-
ease may vary. Hence the application of lipid guidelines
developed in thewest, based on data that had almost no South
Asian participants, in India may merit careful thought and
actually provides a strong rationale for collection of local data5
3.2. Practice environment
The way health-care is delivered may be different in different
regions. Particularly in developingworld the services provided
by intermediaries may be non-existent or under-developed.
Strategies employed in the West for health-care delivery
also may not be directly transferable in the local context and
milieu. The differences lie in:3.3. Social systems
Every country has a different social system that affects its
service delivery, labor, and capital markets. Even within a
country, as large and heterogeneous as India, these systems
may vary from one region to another or even within a region
(for e.g. urban and rural areas). In context of medicine, it
pertains to various aspects of health-care delivery ranging
from referral systems, health care centers, availability of
infrastructure and specialists etc. While many western
countries have a finely streamlined health care delivery
apparatus in place (e.g. UK's NHS) with robust and structured
referral systems, in countries like India health systems are
hugely variable and arbitrary. For instance there may be a
tendency in the primary physicians to try to treat themselves
(hold on to) patients with even serious conditions like acute
myocardial infarction (AMI). Malhotra and co-workers found
that more than a third of patients of AMI present out of win-
dow period in India (36%).6 They found that prior therapy at
local health centers, lack of knowledge of symptoms, and
transportation problems were the main reasons for the hos-
pital delay. Nearly similar findings were also reported by
Rajagopalan et al who found that 36% of AMI patients pre-
sented late. On multivariate analysis they found that being
initially seen by a general practitioner (OR 5.57; 95% CI
1.84e16.8) and an age of over 65 years (OR 3.24; 95% CI
1.06e9.89) were the two most important causes of delay.7
3.4. Openness to ideas
Many societies vary on the ability to adopt a change in prac-
tice. Fortunately, India has always been open to ideas from the
West (perhaps too open), and Indian physicians have always
enthusiastically adopted any change in strategy or even
cutting-edge technology even earlier than other developed
Asian economies (e.g. Japan).
3.5. Patient factors
Perception and awareness about disease and its symptoms
among patients play a critical role in the management of
cardiovascular diseases. In a study, Victor and co-workers
looking at the reasons for delayed door-to-balloon time
(>90 min) found that the hospital related delay occurred only
in 5% cases, while patient related delay was the most impor-
tant factor (90%). They identified delay in taking a decision (by
patient/relatives) for PCI or inability to oblige estimated fi-
nances as the most common factors for the delay. In their
study the overall awareness of AMI and its management was
so low among most of the patients and the relatives, that a
majority of them spent at least 15 min discussing what has
been explained to them with either their kin or their primary
physician on the phone.8
3.6. Civic infrastructure
This play an important role in healthcare delivery, especially
for acute diseaseswhere time is of essence and safe transport
of patient to a hospital a priority. Gross under-provision of
equipped ambulances and trained paramedics, poor condition
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priorities have a large and underappreciated impact on timely
treatment of conditions like acute myocardial infarction and
stroke.
3.7. Product availability
Developing countries have generally opened up their markets
and grown rapidly during the past decade, but application of
new treatment paradigm may still be a challenge in low in-
come groups.
3.8. Labor markets
In spite of developing markets' large populations, there may
be a paucity of trained and qualified professionals. This defi-
ciency is especially acute in sub-specializations as also in
para-medical staff. India for example is yet to have a National
course (Fellowship Program) in Interventional Cardiology or a
program for nurse practitioners, although there seems to be a
huge need in these areas.
3.9. Financial apparatus
: The capital and financial markets in developing countries are
remarkable for their lack of sophistication. There is a paucity
of funds to set up new and advanced health-care facilities
especially in remote areas. On the other hand majority of
patients bear their health-care cost from their own pocket
(Health Insurance still accounts for <10% of all
expenditure).9,10
Finally, it should be remembered that guidelines rely
heavily on data in literature that generally comes from the
best of centers who follow the best practices and that may not
directly be reflective of the real world. Thus for example
comparison of isolated left main angioplasty with CABG may
be widely variable in different areas and centers, reflective of
the short and long term outcomes of respective experts (sur-
geons and intervention cardiologists). Surgical results of best
centers in theworld cannot be extrapolated to those of tier 2 or
3 cities. Here comes the importance of obtaining data that is
more reflective of real world practices. Similarly, theremay be
important and significant differences among patients enrolled
in RCTs and patients encountered commonly in real world
practice. These differences may be in age, race, gender, co-
morbidity, etc. Thus the classical high-dose statin trials,
forming the bedrock of current US cholesterol guidelines, did
not have South Asian participants nor were younger age
groups (typically seen in our country) adequately represented.
3.10. Economic considerations
In most developing countries there may be a wide variability
in affordability of various treatment regimens. Analyzing the
delay in door-to-balloon time (>90 min) Victor and others had
found that those patients who had some form of insurance
scheme had much lower time intervals for financial process
from the billing department (10e15 min) than those who had
no insurance. Likewise CREATE registry had also found that
three quarters of patients with acute coronary syndrome paidthe expenses on their own and only about a tenth had some
form of insurance cover. On the other hand there are indeed
areas where a new therapy may not contribute to a huge
clinical advantage. Thus, while some of the break-through
technologies and inventions may cost a huge amount, some
of the pre-existing therapies with a fraction of cost may be
practically non-inferior. Many examples can be cited:
Warfarin vs. newer anti-coagulants, streptokinase vs. some
newer thrombolytics or even bivalirudin vs. good old un-
fractionated heparin.3.11. Influence of industry
While the innovations and inventions by health-care industry
cannot be belittled, the fact that some products and treatment
models are practically pushed by industry in collaboration
with some subject experts can also not be denied. The
participation of these experts in the process of formulation of
most of the guidelines today is indeed a cause of worry. Thus,
it is rather troubling to note that the chairman and one of two
additional co-chairs of the working panel of the committee
writing the recent controversial ACC/AHA cholesterol guide-
lines, released 2013, had ties to the drug industry at the time
they were asked to lead the panel. Overall, eight of the 15
panelists (>53%) had industry ties. The situation may be no
different for other guidelines, current and past.114. How to develop guidelines
While development of guidelines is a credible endeavor it re-
quires resources; not only financial but the real challenge is
having a critical mass of skilled, experienced professionals
who are not only motivated by community service (and
willing to lend their time, professional expertise and even
material resources) but also have a certain philosophical bent
of mind. In addition they should also possess good interper-
sonal skills and be well-versed with methods of guideline
development and appraisal. Finally, they should have no
conflict of interest as well. Finding a group of these rather
singular individuals is the biggest challenge. Due to this
practical reason, working on the pre-existing guideline (first
identifying and then adapting to current needs) may be the
best option. On the other hand many a times it may not be
possible to find a pre-existing guideline relevant to the issue at
hand; for example guidelines for Rheumatic Fever/Rheumatic
Heart Disease or for reuse of Cath lab/surgical material (situ-
ations peculiar to developing countries) may not be available.
In these cases starting from a scratch may be the only
option.124.1. Pre-existing guidelines
Identifying Appropriate Guidelines e The first part involves
identifying a valid guideline. With availability of internet,
other e-technologies and bibliographic databases, this may
not be a difficult task at present. However, only those guide-
lines should be considered which include a methods section
within the guideline or supporting papers.13,14
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should be carefully appraised as to its contextual and local
relevance and appropriateness. Particularly three areas
should be identified.
1. Where guidelines address the relevant issue. For example
NSTEMI or lipid guidelines using risk calculators to identify
high risk populations.
2. Area of guideline not relevant to the current context. For
example, guideline addressing the issue of LV angiogram in
primary PCI which is not relevant in Indian context
because echocardiography machine and those capable of
performing echocardiogram are already available in Cath
labs (nearly all interventional cardiologists in India know
how to do an echocardiogram for evaluation of LV function
or mechanical complications).
3. Areas where the identified guideline is deficient in relation
to the locally relevant context. For example guidelines for
AMI patients presenting after 12 h of chest pain, patients of
prosthetic valves undergoing PCI, young patients with high
vascular risk, etc may not be existent.
Even when guidelines are relevant to the current issue:
1. The data that led to development of the current guideline
should be re-examined taking into account genetic differ-
ences, differences in practice environment, and particu-
larly keeping in mind, the economic considerations.
Influence of industry in development of that particular
guideline should also be ascertained. Adopting recom-
mendations from another guideline not applicable to cur-
rent context may lead to harm to patients or waste of
resources on ineffective interventions.15
2. Indian data where-ever available should be used to com-
plement or even supplement western data. Difficulty arises
where there is no local data. In that case efforts should be
undertaken to obtain such a data but in its absencewestern
data should be accepted as a substitute.
3. Blind-spot exists in areas which are important. In these
areas consensus between Indian andWestern experts may
be acceptable.
4. Guidelines that aremore practical to prescribe, implement,
and monitor should be preferred for local adoption in
absence of definitive local data.
Adapting Guidelines e The third step involves adapting the
guideline for use within the local healthcare setting. A
multidisciplinary group may be set up to achieve this goal.
While the composition of this group (as also the function)
should include those individuals who would be capable of
developing a new guideline, the work entailed will be much
less: not requiring systematic reviewing and evidence sum-
marizing skills. Adapting the guideline involves restructuring
the recommendations keeping in mind the local re-
quirements: removing the guidelines with weak evidence but
including some other based on local evidence. However, if
some guideline based on strong evidence is removed the
reason for doing so should be clearly stated. Ultimately those
new guidelines should be included whose criteria are well
defined and whose outcome can be objectively measured.4.2. No pre-existing guidelines
There may be several areas which may be relevant to local
practice but guidelines addressing these issues may not exist.
For example non-thrombolysed patients presenting 3 days
after AMI with chest pain or those with atrial fibrillation (AF)
consequent upon rheumatic heart disease or even re-use of
Cath lab/surgical material. WHO has developed a hand-book
to develop clinical guidelines. The following points must be
considered: planning and defining the scope of guideline to be
developed; organizing guideline development group; defining,
declaration and management of conflict of interests; formu-
lating questions and choosing outcomes; evidence retrieval,
assessment and synthesis; grading the quality of evidence
assessment and the strength of recommendations; assessing
cost and resource implications; incorporating values and
preferences; and finally formulating recommendations.16
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Your comments are invited on the above write-up. Two
contrary views/opinions will be published in the next issue of
the Indian Heart Journal in the section “Other Side of the
Moon”. Write to us at editorihj2015@gmail.com.
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